00013 Overview

Research Report Overview: CLSA published a report on HUTCHMED (00013.HK), indicating mixed results for 2025 with sales falling short of forecasts but net profit exceeding expectations.

Future Outlook: The 2026 oncology business guidance suggests a potential commercial recovery, with the new ATTC product line expected to drive growth in performance results.

Target Price Adjustment: The target price for HUTCHMED was lowered from HKD31.4 to HKD30.4, while maintaining an Outperform rating.

Market Activity: Short selling activity was reported at $19.73M with a ratio of 7.785%, indicating significant market interest.

Stock Performance: HUTCHMED's stock opened 0.57% higher, peaked at HKD22.3, and last traded at HKD22.3, reflecting a 5.89% increase with a trading volume of 1.282 million shares.

Financial Results: The company reported a 13% year-over-year decline in total revenue to USD549 million, but net income surged 11 times to USD457 million due to gains from the disposal of non-core businesses, with earnings per share (EPS) at USD0.53.

Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.

Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.

Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.

Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.

Market Performance: The HSI fell by 251 points (0.9%) to close at 26,458, while the HSCEI and HSTECH also experienced declines of 1.1% and 1.5%, respectively, with total market turnover at $276.134 billion.

Tech Stock Movements: Major tech stocks like BABA-W and TENCENT saw significant drops, with BABA-W down 3.2% after a downgrade, while other tech companies also faced declines in short selling ratios.

Chip Stocks Trends: While some chip stocks like HUA HONG SEMI and BIREN TECH saw gains of over 5%, others like SMIC and BIDU-SW experienced slight declines, indicating mixed performance in the sector.

Pharmaceutical Sector Gains: The pharmaceutical sector showed strong performance, with several companies like 3SBIO and REMEGEN surging over 7%, reflecting positive investor sentiment in this industry.

Clinical Development Announcement: HUTCHMED has initiated a global Phase I clinical development program for HMPL-A251, a novel PI3K/PIKK-HER2 Antibody-Targeted Therapy Conjugate.

Study Details: The first patient received the treatment in China, with the study evaluating HMPL-A251 monotherapy in adults with advanced or metastatic HER2-expressing solid tumors across sites in the US and China.

HKEX Tech 100 Index Launch: HKEX has introduced the HKEX Tech 100 Index, its first Hong Kong equity index, which tracks 100 major Hong Kong-listed companies across six innovative sectors, including AI and biotech.

Accessibility for Investors: The index allows for Stock Connect Southbound trading, making it accessible to both global and Chinese Mainland investors, and includes a fast-entry mechanism for newly-listed companies.

Short Selling Data: The article provides detailed short selling data for various companies within the index, highlighting significant short selling ratios for several constituents.

Market Performance: The report includes stock performance changes for various companies, indicating fluctuations in share prices alongside their respective short selling activities.